SCTX

Scribe Therapeutics Inc

15.48

Nov 05 • 3:59 PM ET -1.30 (-7.75%)

15.15

Aftermarket • 6:43 PM ET -0.33 (-2.13%)

Healthcare Biotechnology USA Micro NASD

Nov 04, 8:06 AMScribe Therapeutics to present AHA 2026 data showing two-year durable LDL-C control for PCSK9 therapy STX-1150

Peers: CRSP PRME BEAM NTLA EDIT DTIL SLN ARWR MGX IONS

| Held by: ARKG VTI IWM VXF VTWO IWO IWN IWC BUSM VTWG

Scroll to Statements

Index	RUT
Market Cap	293.06M
Enterprise Value	413.68M
Income	-
Sales	-
Book/sh	-8.71
Cash/sh	2.27
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	98
IPO	Jul 24, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	6.81
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.57
Current Ratio	0.57
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.85
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Sep 02 AMC
EPS/Sales Surpr.	27.58% -38.16%

Insider Own	36.14%
Insider Trans	224.01%
Inst Own	26.36%
Inst Trans	29.34%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-14.08%
SMA50	-31.80%
SMA200	-33.74%
Trades

Shs Outstand	18.93M
Shs Float	12.09M
Short Float	9.25%
Short Ratio	2.96
Short Interest	1.12M
52W High	39.60 -60.91%
52W Low	13.50 14.67%
Volatility	10.74% 12.30%
ATR (14)	2.28
RSI (14)	38.57
Beta	-
Rel Volume	0.77
Avg Volume	377.42K
Volume	291,941

Perf Week	-11.24%
Perf Month	-11.90%
Perf Quarter	-40.46%
Perf Half Y	-
Perf YTD	-38.08%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	57.00
Prev Close	16.78
Price	15.48
Change %	-7.75%

Consensus

Strong Buy

Avg. Price Target

$57.00

Implied Upside

+268.2%

Analysts4incl. previous ratings

Rating Distribution4 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 31, 2026	Initiated	HH.C. Wainwright	Buy	$60	+287.6%
Aug 18, 2026	Initiated	WWells Fargo	Overweight	$60	+287.6%
Aug 18, 2026	Initiated	LLeerink Partners	Outperform	$37	+139.0%
Aug 18, 2026	Initiated	GGuggenheim	Buy	$50	+223.0%

Today 08:00AM	Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences (GlobeNewswire) -7.75%
Nov-04-26 08:00AM	Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026 (GlobeNewswire)
Sep-28-26 03:11PM	Cathie Wood Makes $64 Million Bet on Two Stocks (GuruFocus.com)
Sep-22-26 07:10AM	Beyond Meta, Cathie Woods ARKG Loads Up On These 4 Biotech Names (Stocktwits)
Sep-02-26 04:05PM	Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire) +6.55%
08:00AM	Loading…
Sep-01-26 08:00AM	Scribe Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.04%
Aug-31-26 09:45AM	Deere upgraded, Lumentum initiated: Wall Street's top analyst calls (The Fly) +7.38%
Aug-18-26 09:37AM	Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls (The Fly) +27.94%
Jul-27-26 04:08PM	Scribe's Genetic Editing Aims to Prevent Heart Attacks (Barrons.com) -12.38%
04:05PM	Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement (GlobeNewswire)
Jul-24-26 02:45PM	Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPO (GuruFocus.com)

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AH Bio Fund II, L.P.	10% Owner	Jul 27 '26	Buy	15.00	333,333	4,999,995	2,385,075	Jul 29 07:09 PM
GORDON CARL L	Director	Jul 27 '26	Buy	15.00	1,000,000	15,000,000	1,348,825	Jul 29 06:50 PM
ORBIMED ADVISORS LLC	Director	Jul 27 '26	Buy	15.00	1,000,000	15,000,000	1,348,825	Jul 29 06:47 PM
Aghazadeh Behzad	Director	Jul 24 '26	Buy	15.15	2,383,333	36,115,495	3,080,983	Jul 28 09:30 PM
Aghazadeh Behzad	Director	Jul 28 '26	Buy	18.25	7,905	144,266	3,088,888	Jul 28 09:30 PM
Lucas Svetlana	Chief Business Officer	Jul 23 '26	Buy	15.00	3,000	45,000	3,000	Jul 27 09:42 PM
Parrot David	Chief Financial Officer	Jul 23 '26	Buy	15.00	2,666	39,990	1,333	Jul 27 09:20 PM

Scribe Therapeutics, Inc. is a clinical-stage biotechnology company. It is engaged in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded in June 2017 by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Alameda, CA.

Co-FounderDr. Benjamin L. Oakes Ph.D.

CFO & TreasurerMr. David L. Parrot M.B.A.

Chief Operating OfficerDr. Svetlana Lucas Ph.D.

Co-Founder & Scientific AdvisorDr. Jennifer A. Doudna Ph.D.

Co-Founder & VP of External InnovationMr. Brett T. Staahl Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SCTX

Scribe Therapeutics Inc

Upgrade your Finviz experience